Pfizer’s Safe House: Peter Honig Builds A Regulatory Model For The Future
Executive Summary
In Vivo talks to Pfizer SVP for worldwide safety and regulatory Peter Honig on the challenges of establishing – and then maintaining – the confidence of a diverse array of constituencies in the safe, effective use of medicines for a $50 billion business.
You may also be interested in...
Market Access: Japan Is Not An Add-On For Medtech Manufacturers
Too risky? Too costly? Global medtech innovators have tended to look at Japan as a market they might graduate to after cracking the US and EU. But Japan has changed in recent years and offers opportunities to medtech companies with products for unmet needs, as long as those firms are willing to commit themselves to understanding the dynamics of the market and its unique aspects.
Access To Medicines Innovation: Seven Points To A Sustainable System
The Boston Consulting Group convened a roundtable of market access executives from leading biopharma companies in the US, Europe and Japan to reach consensus on how to finance the cost of health care. The group's working paper considers various approaches to financing high-quality care, with an initial emphasis on advocating for change among payers in Europe.
First Approvals Under EMA’s Adaptive Pathways May Be Just A Few Years Away
The first marketing authorizations under the European Medicines Agency’s hotly debated adaptive pathways concept for getting drugs to patients faster could be granted in just a few years’ time.